Eleven-Nineteen-Leukemia Protein IN-3 (Compound 28) (30 mg/kg; p.o.; single dose) shows oral exposure characteristics[1].
Eleven-Nineteen-Leukemia Protein IN-3 (5 mg/kg; i.v.; single dose) highly exposes in vivo[1].
Pharmacokinetic (PK) study in Male BALB/c mice[1]
| Administration | t1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUC0-t (h?ng/mL) | AUC0-∞ (h?ng/mL) | MRT0-∞ (h) |
| p.o. | 5.2 | 0.5 | 71.8 | 257 | 272 | 5.5 |
|
| Administration | t1/2 (h) | AUC0-t (h?ng/mL) | AUC0-∞ (h?ng/mL) | Vss (L/kg) | CL (mL/min/kg) | MRT0-∞ (h) | F (%) |
| i.v. | 4.0 | 8290 | 8690 | 0.8 | 9.6 | 1.3 | 0.5 |
| Animal Model: | Male BALB/c mice[1]. |
| Dosage: | 30 mg/kg. |
| Administration: | Oral gavage; single dose. |
| Result: | Showed an oral activity. |
| Animal Model: | Male BALB/c mice[1]. |
| Dosage: | 5 mg/kg. |
| Administration: | Intravenous injection; single dose. |
| Result: | Exhibited efficacy. |